CIK 0001347178
- Accelerated filer
Vanda Pharmaceuticals Inc.
Sign in to watch- Ticker
- VNDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 030491827
- Phone
- +1 202-734-3400
- Business address
- 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC, 20037
- Open-market buys, last 90 days
- $38,094
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$38,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-02-28 | Wijkstrom Joakim SVP, Chief Marketing Officer | Grant or award | +32,700 | 107,252 | ||
| 2022-02-28 | Wijkstrom Joakim SVP, Chief Marketing Officer | Grant or award · Stock Option (Right to Buy) | +77,500 | 77,500 | ||
| 2022-02-28 | Polymeropoulos Mihael Hristos President and CEO | Grant or award | +115,000 | 1,389,862 | ||
| 2022-02-28 | Polymeropoulos Mihael Hristos President and CEO | Grant or award · Stock Option (Right to Buy) | +275,000 | 275,000 | ||
| 2022-02-28 | Moran Kevin Patrick SVP, CFO & Treasurer | Grant or award | +32,700 | 131,996 | ||
| 2022-02-28 | Moran Kevin Patrick SVP, CFO & Treasurer | Grant or award · Stock Option (Right to Buy) | +77,500 | 77,500 | ||
| 2022-02-28 | Birznieks Gunther SVP, Business Development | Grant or award | +32,700 | 204,408 | ||
| 2022-02-28 | Birznieks Gunther SVP, Business Development | Grant or award · Stock Option (Right to Buy) | +77,500 | 77,500 | ||
| 2021-12-01 | Polymeropoulos Mihael Hristos President and CEO | Option exercise | +71,676 | $4.88 | $350K | 1,321,062 |
| 2021-12-01 | Polymeropoulos Mihael Hristos President and CEO | Sale | −46,200 | $16.00 | $739K | 1,274,862 |
| 2021-12-01 | Polymeropoulos Mihael Hristos President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −71,676 | 0 | ||
| 2021-11-30 | Polymeropoulos Mihael Hristos President and CEO | Option exercise | +78,324 | $4.88 | $382K | 1,299,386 |
| 2021-11-30 | Polymeropoulos Mihael Hristos President and CEO | Sale | −50,000 | $16.49 | $824K | 1,249,386 |
| 2021-11-30 | Polymeropoulos Mihael Hristos President and CEO | Option exercise · Employee Stock Option (Right to Buy) | −78,324 | 71,676 | ||
| 2021-09-15 | Jones Aranthan II Chief Corp. Affairs Officer | Option exercise | +4,277 | $12.27 | $52K | 90,962 |
| 2021-09-15 | Jones Aranthan II Chief Corp. Affairs Officer | Option exercise | +7,842 | $11.32 | $89K | 98,804 |
| 2021-09-15 | Jones Aranthan II Chief Corp. Affairs Officer | Sale | −16,824 | $16.49 | $277K | 81,980 |
| 2021-09-15 | Jones Aranthan II Chief Corp. Affairs Officer | Option exercise · Employee Stock Option (Right to Buy) | −4,277 | 33,224 | ||
| 2021-09-15 | Jones Aranthan II Chief Corp. Affairs Officer | Option exercise · Employee Stock Option (Right to Buy) | −7,842 | 47,158 | ||
| 2021-09-09 | Mitchell Stephen Ray Director | Option exercise | +5,985 | $10.57 | $63K | 15,200 |
Page 9 of 20 · 387 trades